Clinical trial
A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions
NCT02943213 is registered in ClinicalTrials.gov with Cycle Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions
- Lead sponsor
- Cycle Pharmaceuticals Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- December 31, 2016
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute intermittent porphyria, adjunct in the treatment of tetanus, anti-psychotic, control manifestations of the manic type of mani-depressive illness, control nausea and vomiting, management of manifestations of psychotic disorders, relief of intractable hiccups, relief of restlessness and apprehension before surgery, treatment of schizophrenia